Show summary Hide summary
The global diabetes map shifted recently when the International Diabetes Federation gave formal recognition to a fifth type of diabetes. This designation spotlights a condition tied to chronic malnutrition that affects millions in low- and middle-income countries and forces clinicians and health systems to rethink diagnosis and treatment.
What clinicians mean by Type 5 diabetes
Type 5 diabetes, often called malnutrition-related diabetes mellitus (MRDM), differs from the familiar Type 1 and Type 2 forms. It does not primarily arise from insulin resistance or classic autoimmune destruction. Instead, long-term undernutrition impairs pancreatic development and reduces insulin-producing capacity.
Eggs every day for months: simple check reveals shocking blood test result
Popular childhood food ingredient may raise adult anxiety: study
- Cause: Prolonged nutritional deficits during childhood or adolescence.
- Mechanism: Underdeveloped pancreatic tissue that cannot secrete adequate insulin.
- Typical patients: Lean adolescents and young adults living in areas of food insecurity.
How MRDM contrasts with other diabetes types
Understanding MRDM requires a quick comparison with better-known types:
- Type 1: Autoimmune loss of insulin production.
- Type 2: Progressive insulin resistance linked to lifestyle and metabolic factors.
- Type 3c: Diabetes due to pancreatic damage from disease or surgery.
- Gestational diabetes: Temporary glucose intolerance during pregnancy.
MRDM stands apart because traditional treatment approaches, like high-dose insulin, may not work and can even harm patients who face food shortages.
Where this disease is most common
MRDM predominates in resource-limited regions. Reports point to higher numbers across parts of Asia and sub-Saharan Africa. The disease targets communities with chronic food insecurity and insufficient protein or calories during early life.
Experts estimate the burden at millions worldwide, and some research groups suggest numbers could be as high as 25 million people. Limited surveillance and inconsistent case definitions have made accurate counts difficult.
Why recognition matters now
The condition was first described decades ago, then fell in and out of official classifications. Recent validation by the IDF restores a formal label and creates an opening for coordinated action.
- Recognition helps prioritize research funding.
- It enables the development of diagnostic criteria and treatment guidelines.
- It can improve clinician training in affected regions.
Treatment dilemmas and emerging strategies
Treating MRDM is complex. Purely following insulin protocols used for Type 1 can trigger dangerous hypoglycemia in patients who also face irregular food access.
Clinical risks
- Inappropriate insulin dosing can lower blood sugar to life-threatening levels.
- Standard monitoring tools may be unaffordable or unavailable in many settings.
- Untreated or mistreated MRDM increases risk of nerve, kidney, and eye damage.
Therapeutic approaches under study
- Low-dose insulin regimens tailored to individual needs.
- Oral medications that stimulate residual insulin secretion.
- Nutrition-focused care to correct the root cause: long-standing malnutrition.
Researchers and clinicians stress the need to pair glucose management with programs that address calorie and protein deficits.
Building tools for detection and care
To close gaps in care, the IDF created a dedicated working group. Their tasks include drafting formal diagnostic standards, practical treatment algorithms, and training modules for healthcare workers in low-resource environments.
- Goal: Clear case definitions to improve diagnosis.
- Goal: Evidence-based guidance that reduces treatment harm.
- Goal: Capacity building for frontline providers.
Public health implications and next steps
Experts warn that without action, MRDM will keep causing preventable disability and death. Accurate surveillance, clinical trials, and nutrition interventions must move in parallel. The IDF working group, led by clinicians who have long advocated for recognition, will convene researchers and health authorities to translate the new classification into practice.
